Elizabeth I. Buchbinder, MD

Elizabeth I. Buchbinder, MD

Medical Oncology

Contact Information

Office Phone Number








Senior Physician
Assistant Professor of Medicine, Harvard Medical School

Clinical Interests

Immunotherapy, Melanoma, Targeted therapies

Diseases Treated

Board Certification

  • Internal Medicine
  • Medical Oncology


  • Beth Israel Deaconess Medical Center, Medical Oncology


  • Beth Israel Deaconess Medical Center, Internal Medicine

Medical School

  • Tufts University School of Medicine


    • Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma? Cancer J. 2024 Mar-Apr 01; 30(2):120-125. View in: Pubmed

    • Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer. Cancers (Basel). 2024 Jan 24; 16(3). View in: Pubmed

    • Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024 Feb 17; 403(10427):632-644. View in: Pubmed

    • Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment. Cancer Immunol Immunother. 2024 Jan 18; 73(1):17. View in: Pubmed

    • Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer. Semin Arthritis Rheum. 2024 Feb; 64:152335. View in: Pubmed

    • Proceedings from the Melanoma Research Foundation Mucosal Melanoma Meeting (December 16, 2022, New York, USA). Pigment Cell Melanoma Res. 2023 Nov; 36(6):542-556. View in: Pubmed

    • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. J Immunother Cancer. 2023 10; 11(10). View in: Pubmed

    • Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature. Adv Radiat Oncol. 2024 Jan; 9(1):101310. View in: Pubmed

    • Exploring Influencing Factors of Anxiety Improvement Following Mindfulness-Based Music Therapy in Young Adults with Cancer. J Music Ther. 2023 Jun 03; 60(2):131-148. View in: Pubmed

    • A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma. Invest New Drugs. 2023 08; 41(4):551-555. View in: Pubmed

    • Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy. J Immunother. 2023 06 01; 46(5):192-196. View in: Pubmed

    • A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition. Invest New Drugs. 2023 Jun; 41(3):365-370. View in: Pubmed

    • Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors. Cancer. 2023 06 15; 129(12):1904-1918. View in: Pubmed

    • Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study. Lancet Rheumatol. 2023 May; 5(5):e274-e283. View in: Pubmed

    • Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar 02; 388(9):813-823. View in: Pubmed

    • Exploring Young Adults' Perspectives of Participation in a Mindfulness-Based Music Therapy Intervention Before and During the COVID-19 Pandemic. J Adolesc Young Adult Oncol. 2023 08; 12(4):569-576. View in: Pubmed

    • Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 02 01; 9(2):251-260. View in: Pubmed

    • Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders. Front Immunol. 2022; 13:1069444. View in: Pubmed

    • Evolving Management of Stage IV Melanoma. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e397478. View in: Pubmed

    • Impact of Precision Medicine in Oncology: Immuno-oncology. Cancer J. 2023 Jan-Feb 01; 29(1):15-19. View in: Pubmed

    • Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. Eur J Cancer. 2023 03; 181:188-197. View in: Pubmed

    • Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023 02 01; 129(3):367-375. View in: Pubmed

    • Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma. JAAD Case Rep. 2022 Sep; 27:162-166. View in: Pubmed

    • Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Ann Oncol. 2022 09; 33(9):968-980. View in: Pubmed

    • Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv. 2022 Apr 29; 8(17):eabl6339. View in: Pubmed

    • Adjuvant Pembrolizumab versus IFNa2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 03 01; 12(3):644-653. View in: Pubmed

    • Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. Eur J Cancer. 2022 02; 162:22-33. View in: Pubmed

    • Cancer Therapy Targeting CD47/SIRPa. Cancers (Basel). 2021 Dec 11; 13(24). View in: Pubmed

    • Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer. J Pain Symptom Manage. 2022 Apr; 63(4):e357-e363. View in: Pubmed

    • Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial. J Immunother Cancer. 2021 11; 9(11). View in: Pubmed

    • Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. J Immunother. 2021 10 01; 44(8):307-318. View in: Pubmed

    • Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: A retrospective cohort study. J Am Acad Dermatol. 2022 08; 87(2):403-406. View in: Pubmed

    • Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med. 2021 04; 10(8):2627-2635. View in: Pubmed

    • A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654. View in: Pubmed

    • Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother. 2021 Aug; 70(8):2209-2221. View in: Pubmed

    • Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat Med. 2021 03; 27(3):515-525. View in: Pubmed

    • Immune Checkpoint Therapies for Melanoma. Hematol Oncol Clin North Am. 2021 02; 35(1):99-109. View in: Pubmed

    • Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. Sci Rep. 2020 10 16; 10(1):17536. View in: Pubmed

    • Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011. View in: Pubmed

    • Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020 08 15; 126(16):3758-3767. View in: Pubmed

    • Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Manag. 2020 Jun 15; 7(2):MMT41. View in: Pubmed

    • Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. JCO Oncol Pract. 2020 09; 16(9):e933-e942. View in: Pubmed

    • Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311. View in: Pubmed

    • Severe Radiation Necrosis Refractory to Surgical Resection in Patients with Melanoma and Brain Metastases Managed with Ipilimumab/Nivolumab and Brain-Directed Stereotactic Radiation Therapy. World Neurosurg. 2020 07; 139:226-231. View in: Pubmed

    • The Evolution of Adjuvant Therapy for Melanoma. Curr Oncol Rep. 2019 11 25; 21(12):106. View in: Pubmed

    • A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019 08; 25(8):1243-1250. View in: Pubmed

    • Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019 03 29; 7(1):89. View in: Pubmed

    • Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019 02 18; 7(1):49. View in: Pubmed

    • Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. Melanoma Res. 2019 02; 29(1):70-76. View in: Pubmed

    • Immunotherapy Toxicity. Hematol Oncol Clin North Am. 2019 04; 33(2):275-290. View in: Pubmed

    • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24. View in: Pubmed

    • Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402. View in: Pubmed

    • First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195. View in: Pubmed

    • Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. Cancer Immunol Res. 2017 12; 5(12):1133-1140. View in: Pubmed

    • An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221. View in: Pubmed

    • Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 07; 124(1):98-103. View in: Pubmed

    • Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions. Clin Cancer Res. 2017 Aug 15; 23(16):4671-4679. View in: Pubmed

    • The Phoenix Rises: The Rebirth of Cancer Immunotherapy. Clin Chem. 2017 07; 63(7):1190-1195. View in: Pubmed

    • Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2017 05; 133(1):221. View in: Pubmed

    • Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05; 5(5):357-362. View in: Pubmed

    • Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition. J Immunother. 2017 01; 40(1):31-35. View in: Pubmed

    • A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med. 2016 11; 5(11):3041-3050. View in: Pubmed

    • A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52. View in: Pubmed

    • Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol. 2016 09; 129(3):389-393. View in: Pubmed

    • Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016 Jul; 17(7):943-955. View in: Pubmed

    • Biomarkers in Melanoma: Lessons from Translational Medicine. Trends Cancer. 2016 06; 2(6):305-312. View in: Pubmed

    • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. View in: Pubmed

    • CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016 Feb; 39(1):98-106. View in: Pubmed

    • Melanoma in 2015: Immune-checkpoint blockade - durable cancer control. Nat Rev Clin Oncol. 2016 Feb; 13(2):77-8. View in: Pubmed

    • Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol. 2015; 5:202. View in: Pubmed

    • Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis. J Cutan Pathol. 2016 Jan; 43(1):57-63. View in: Pubmed

    • Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015 Sep; 125(9):3377-83. View in: Pubmed

    • Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15. View in: Pubmed

    • Cytotoxic T-lymphocyte antigen-4 blockade in melanoma. Clin Ther. 2015 Apr 01; 37(4):755-63. View in: Pubmed

    • Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Mol Cancer Ther. 2014 Dec; 13(12):3210-8. View in: Pubmed

    • Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am. 2014 Jun; 28(3):571-83. View in: Pubmed

    • Parents' experience of their child's first psychiatric breakdown: "welcome to hell". Soc Work Health Care. 2013; 52(6):538-57. View in: Pubmed

    • Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7. View in: Pubmed

    • Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2. J Immunother. 2012 Nov-Dec; 35(9):711-5. View in: Pubmed

    • Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e615-22. View in: Pubmed

    • Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108. View in: Pubmed

    • Signaling between focal adhesion kinase and trio. J Biol Chem. 2003 Apr 11; 278(15):13265-70. View in: Pubmed


    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Elizabeth I. Buchbinder, MD

    About Our Ratings

    Physician Star Rating Comment Block

    Discovery and Insights